Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Jul 26 - Jul 31
PubMed PMID: 22295124
an increase in type II collagen and proteoglycans
Mol Cell Endocrinol
it is well tolerated and can be used topically and orally
inducing rapid and sustained KRASG12C degradation leading to suppression of MAPK signaling in both homozygous and heterozygous KRASG12C cell lines
PF-04929113 free base sgenin PubMed PMID: 22295124PF 04929113, also known as SNX 5422; is a synthetic prodrug targeting the human heat shock protein 90 (Hsp90) with potential antineoplastic activity. Although the mechanism of action remains to be fully elucidated, Hsp90 inhibitor SNX 5542 is rapidly converted to SNX 2112, which accumulates in tumors relative to normal tissues. SNX 2112 inhibits Hsp90, which may result in the proteasomal degradation of oncogenic client proteins, including HER2 ERBB2,
US$ 155.50
US$ 431.00
US$ 248.00
US$ 335.50
US$ 235.50
US$ 13250.00
US$ 201.50